Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Vaccines

BioNTech plans mRNA vaccine plant in Africa

by Michael McCoy
October 30, 2021 | A version of this story appeared in Volume 99, Issue 40

BioNTech has followed Moderna in announcing plans to build a plant in Africa for messenger RNA (mRNA)–based vaccines for COVID-19 and other diseases. BioNTech says it will begin construction in mid-2022, though it has not specified a location. Amid criticism that it is neglecting the developing world, Moderna said in October that it will spend $500 million on an mRNA facility at an unspecified location in Africa. On Oct. 26, Moderna said it will make up to 110 million doses of its COVID-19 vaccine available to the African Union.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.